Publication: Recurrencias, hemorragias y mortalidad relacionada durante la anticoagulación y tras la suspensión del tratamiento en pacientes mayores de 75 años con un primer episodio de enfermedad tromboembólica venosa no provocada
Loading...
Files
Official URL
Full text at PDC
Publication Date
2019-01-24
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
Las guías actuales recomiendan mantener la anticoagulación al menos 3 meses en pacientes con un primer episodio de enfermedad tromboembólica venosa (ETV) no provocada. En los pacientes con riesgo bajo o moderado de hemorragia, sugieren realizar tratamiento extendido (sin fecha de fin programada). Si el riesgo de hemorragia es alto, recomiendan tres meses de anticoagulación antes que tratamientos extendidos.OBJETIVOS: 1. Conocer la frecuencia de recidivas y de hemorragias graves durante la anticoagulación, después de los tres meses iniciales de tratamiento, en pacientes del registro RIETE mayores de 75 años con un primer episodio de ETV no provocada. 2. Conocer la mortalidad producida por las recidivas y por las hemorragias graves durante la anticoagulación, después de los tres meses iniciales de tratamiento, en pacientes del registro RIETE mayores de 75 años con un primer episodio de ETV no provocada. 3. Conocer la frecuencia de recidivas y de hemorragias graves tras la suspensión de la anticoagulación en pacientes del registro RIETE mayores de 75 años con un primer episodio de ETV no provocada. 4. Conocer la mortalidad producida por las recidivas y por las hemorragias graves tras la suspensión de la anticoagulación en pacientes del registro RIETE mayores de 75 años con un primer episodio de ETV no provocada. 5. Identificar los factores predictores de hemorragia grave durante la anticoagulación después de los tres meses iniciales y de recidiva tras la suspensión del tratamiento en pacientes del registro RIETE mayores de 75 años con un primer episodio de ETV no provocada...
Current guidelines recommend in patients with a first episode of unprovoked venous thromboembolism treatment with anticoagulation at least for 3 months. In patients with a low or moderate bleeding risk, suggest extended anticoagulant therapy (no scheduled stop date). In high bleeding risk patients recommend 3 months of anticoagulant therapy over extended treatment.OBJECTIVES: 1. To know the frecuency of recurrences and major bleeding during anticoagulant therapy beyond the third month in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease. 2. To know recurrence related mortality and major bleeding related mortality during anticoagulant therapy beyond the third month in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease. 3. To know the frecuency of recurrences and major bleeding after discontinuing anticoagulant therapy in patients in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease. 4. To know recurrence related mortality and major bleeding related mortality after discontinuing anticoagulant therapy in patients in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease. 5. To identify prediction factors of major bleeding during anticoagulant therapy and of recurrence after discontinuing it in patients in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease...
Current guidelines recommend in patients with a first episode of unprovoked venous thromboembolism treatment with anticoagulation at least for 3 months. In patients with a low or moderate bleeding risk, suggest extended anticoagulant therapy (no scheduled stop date). In high bleeding risk patients recommend 3 months of anticoagulant therapy over extended treatment.OBJECTIVES: 1. To know the frecuency of recurrences and major bleeding during anticoagulant therapy beyond the third month in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease. 2. To know recurrence related mortality and major bleeding related mortality during anticoagulant therapy beyond the third month in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease. 3. To know the frecuency of recurrences and major bleeding after discontinuing anticoagulant therapy in patients in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease. 4. To know recurrence related mortality and major bleeding related mortality after discontinuing anticoagulant therapy in patients in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease. 5. To identify prediction factors of major bleeding during anticoagulant therapy and of recurrence after discontinuing it in patients in patients of the RIETE registry aged >75 years with a first episode of unprovoked venous thromboembolic disease...
Description
Tesis de la Universidad Complutense de Madrid, Facultad de Medicina, Departamento de Medicina Preventiva, Salud Pública e Historia de la Ciencia, leída el 17-09-2018